A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine

Bristol-Myers Squibb145 个研究点分布在 9 个国家开始时间: 2001年2月最近更新: 2011年5月4日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方
试验地点: 145

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).

详细描述

This is a multinational, 2-arm study. Patients in 1 arm receive BMS-232632 plus EFV placebo capsules. Patients in the other arm receive EFV plus BMS-232632 placebo. Both arms also receive a fixed dose of ZDV-3TC.

研究设计

研究类型: Interventional
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 16 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

研究点 (145)

Loading locations...

相似试验

已完成

2 期

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV DrugsHIV Infections

NCT00002240Bristol-Myers Squibb

已完成

3 期

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsHepatitis C Virus Infection

NCT01718145Bristol-Myers Squibb258

已完成

3 期

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsHepatitis C

NCT01497834Bristol-Myers Squibb224

已完成

3 期

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis CHepatitis C

NCT01448044Bristol-Myers Squibb152

已完成

2 期

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus InfectionHepatitis B, Chronic

NCT03982186Janssen Sciences Ireland UC471